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During early stages of brain development, neuroepithelial stem cells undergo intense proliferation as neurogenesis begins. Fibroblast growth
factor 2 (FGF2) has been involved in the regulation of these processes, and although it has been suggested that they work in an autocrine–paracrine
mode, there is no general agreement on this because the behavior of neuroepithelial cells is not self-sufficient in explants cultured in vitro.
In this work, we show that during early stages of development in chick embryos there is another source of FGF2, besides that of the
neuroepithelium, which affects the brain primordium, since the cerebrospinal fluid (E-CSF) contains several isoforms of this factor. We also
demonstrate, both in vitro and in vivo, that the FGF2 from the E-CSF has an effect on the regulation of neuroepithelial cell behavior, including cell
proliferation and neurogenesis.
In order to clarify putative sources of FGF2 in embryonic tissues, we detected by in situ hybridization high levels of mRNA expression in
notochord, mesonephros and hepatic primordia, and low levels in brain neuroectoderm, corroborated by semiquantitative PCR analysis.
Furthermore, we show that the notochord segregates several FGF2 isoforms which modify the behavior of the neuroepithelial cells in vitro. In
addition, we show that the FGF2 ligand is present in the embryonic serum; and, by means of labeled FGF2, we prove that this factor passes via the
neuroepithelium from the embryonic serum to the E-CSF in vivo.
Considering all these results, we propose that, in chick embryos, the behavior of brain neuroepithelial stem cells at the earliest stages of
development is influenced by the action of the FGF2 contained within the E-CSF which could have an extraneural origin, thus suggesting a new
and complementary way of regulating brain development.
© 2006 Elsevier Inc. All rights reserved.Keywords: FGF2; Cerebrospinal fluid; Neuroepithelial precursor behavior; Neurogenesis; Brain development; Stem cells; Neural tube; Chick embryosIntroduction
In vertebrates, early brain development takes place at the
expanded anterior end of the neural tube. At these early
developmental stages, the brain wall is formed by a pseudo-
stratified neuroepithelium, mainly built by pluripotent stem
cells. This neuroepithelial wall also encloses a large cavity
containing the embryonic cerebrospinal fluid (E-CSF).⁎ Corresponding author.
E-mail address: gato@med.uva.es (A. Gato).
0012-1606/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2006.05.010The highly dynamic cellular behavior of neuroepithelial stem
cells at these stages of development includes both an intense
proliferation phase in which these cells increase in number to
generate a large number of progenitor cells in the central
nervous system (CNS) and the initiation of neurogenesis. The
mechanisms involved in controlling in vivo replication and
differentiation of neuroepithelial stem cells are not fully known.
It has been suggested that proliferation and neurogenesis are
sequentially driven during the ontogeny of neural cells, and that
morphogenetic factors involved in the inducing the proliferation
of neuroepithelial cells also promote their transition to the
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and McKay, 2002). Although it has been proposed that in
different species, several growth factors could be involved in
the regulation of these processes through different sorts of
interactions, several studies conducted in many different
experimental conditions have shown that FGF2 and, subse-
quently, EGF are involved in regulating the proliferation and
differentiation of neural precursors at early stages of develop-
ments (Tropepe et al., 1999; Vaccarino et al., 1999a; Junier,
2000; Ford-Perriss et al., 2001; Panchision and McKay, 2002;
Dono, 2003). However, so as to understand what influences
embryonal brain development, it is important to know of the
origin and modus operandi of its regulating factors.
Regarding the role of FGF2 in neuroepithelial develop-
ment, it has been suggested that it acts in an intracrin (Bikfalvi
et al., 1995; Davis et al., 1997) and autocrine–paracrine
manner (Vaccarino et al., 1999a,b; Panchision and McKay,
2002, among others). In this regard, it has been shown that
FGF2 immunoreactivity (Kalcheim and Neufeld, 1990; Dono
and Zeller, 1994; Raballo et al., 2000; Dono, 2003) or mRNA
(Zúñiga Mejia Borja et al., 1993; Savage and Fallon, 1995;
Ozawa et al., 1996; Han, 1997 Vaccarino et al., 1999a) is
expressed from early stages of development in a developmen-
tally regulated manner at numerous distinct sites, including the
proliferative neuroepithelium in several species, specially in
rodents. In addition, FGF2 signaling involves high affinity
transmembrane tyrosine-kinase receptors (FGFR1 to FGFR4),
which are also expressed at distinct sites during embryogen-
esis in a developmentally regulated manner, including the
CNS (Fayein et al., 1992; Ozawa et al., 1996; Wilke et al.,
1997; Okada-Ban et al., 2000; Reuss and von Bohlen und
Halbach, 2003).
In the last few years, it has been shown that the intra-cavity
E-CSF has an important effect on brain development. For
instance, we have recently reported that E-CSF, which has a
complex protein composition (Gato et al., 2004; Parada et al.,
2005a), exerts a trophic action on the neuroepithelial cells,
promoting their survival, proliferation and neurogenesis, and
has a role in regulating the expression of some genes involved in
the patterning of the CNS, i.e., otx2 (Gato et al., 2005; Parada et
al., 2005b). In this regard, it has been suggested that CSF is
involved in the regulation of cortical histogenesis during fetal
and early postnatal stages (Miyan et al., 2003). Moreover, the
theory that FGF2 has an autocrine–paracrine action on
neuroepithelial cells implies a tissue self-sufficiency in
regulating cell behavior; we have also demonstrated that
neuroepithelial explants cultured in vitro with a chemically
defined medium are unable to self-induce a normal level of
proliferation and neurogenesis of neuroepithelial cells, and that
they require the action of specific E-CSF components on such
cells (Gato et al., 2005).
However, there are many reports that enable us to presume
that the FGF2 could act on the neuroepithelium by means other
than those autocrine–paracrine previously proposed. FGF2 is
known to be one of the prototypic heparin binding growth
factors (HBGF) and may act over longer distances, as it has
been reported that members of the HBGF family may besecreted at a certain distance from their target cells. It is also
known that FGF2 normally travels via extracellular routes
bound to heparan-sulphate proteoglycans (HSPG), facilitating
the displacement of the growth factor, and protecting them
from enzymatic degradation, as well as, in some cases,
concentrating them near the target cells or working in
collaboration with the FGF2-receptor union (Yayon et al.,
1991, Nugent and Edelman, 1992, Joseph et al., 1996,
Brickman et al., 1998). These findings indicate that during
development FGF2 is a factor which can act at a distance
between cells of the same or different structure. In this regard, it
has been shown that proteoglycans are present inside the brain
cavity of chick embryos during the period of maximum
cerebral expansion. (Gato et al., 1993, Alonso et al., 1999).
Considering all this data, we hypothesize that a source of
FGF2 other than the neuroepithelium itself could be necessary
to maintain normal in vivo behavior of neuroepithelial cells, and
that the E-CSF may provides the neuroepithelium with this
function during early development.
In these work, we show that in chick embryos at early
stages of CNS development, E-CSF contains FGF2, that this
FGF2 is involved in regulating the behavior of neuroectoder-
mal cells, including cell proliferation and neurogenesis, and
our results suggest that the FGF2 of the E-CSF might come
from the embryonic serum and may have, at least in part, an
extraneural origin.Material and methods
Obtaining E-CSF and embryonic serum
Fertile chicken eggs were incubated at 38°C in a humidified atmosphere to
obtain chick embryos at developmental stage HH25 (Hamburger and Hamilton,
1951). To obtain E-CSF, after incubation, the extraembryonic membranes were
removed, the embryos were rinsed twice in sterile saline solution and placed in a
dry Petri dish, and surrounding fluid was aspirated to avoid CSF contamination.
A glass microneedle (30-μm inner diameter at the tip) connected to a
microinjector (Medical System PLI 100) was carefully placed on the middle
of the mesencephalic cavity under dissecting microscope control. CSF was
slowly aspirated, avoiding contact with the neuroepithelial wall so as to obtain
samples not contaminated by neuroepithelial cells. A sufficient number of
embryos were used to obtain an adequate amount of CSF. To minimize protein
degradation, E-CSF samples were kept at 4°C during this procedure, and
immediately afterwards, they were aliquoted, lyophilized, and frozen at −40°C
until used.
Although the organotypic cultures in which this E-CSF was used were made
with mesencephalic neuroectodermal tissue from embryos at HH19–20, to be
cultured 24 h in vitro (up to the equivalent of stage HH23), the E-CSF was
obtained from embryos at stage HH25 in order to obtain a reasonable amount of
this fluid (approximately 5 μl/embryo). It has been reported that the protein
composition of the E-CSF monitored by SDS-polyacrylamide gel electropho-
resis and silver staining is not qualitatively modified between HH19 to 28 (Gato
et al., 2004).
To obtain embryonic serum, blood from stage HH25 chick embryos was
extracted “in vivo”. A small window was made in the eggshell, the vitelline and
amniotic membranes were cut and separated by microdissection. Subsequently a
small support was placed under the embryo to facilitate holding in place and
improve visualization. The blood was obtained by microaspiration in the
outflow tract of the embryonic heart with a glass microneedle of 20-μm inner
diameter connected to a microinjector (Medical System PLI 100). The blood
from different embryos was pooled and immediately centrifuged, and the serum
fraction aliquoted, lyophilized, and stored at −40°C until used.
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Organotypic cultures of mesencephalic neuroectoderm were performed as
described in Gato et al. (2005). Briefly, this took place as follows: chick embryos
at HH20 were dissected out of extraembryonic membranes, and the ectoderm
and mesoderm covering the mesencephalic vesicle was removed using a
tungsten needle. Following this, the mesencephalic roof of the neuroepithelium
was cut with microscissors. The explants, after extensive washing in a serum-
free medium, were placed on small pieces of Millipore filters (0.8-μm pore size)
previously boiled in distilled and de-ionized water. After equilibrating the filters
in a serum-free medium for 15 min, the explants were placed on the filter with
the apical surface in close contact with the filter. To avoid the detachment of the
explants, these were peripherically fixed to the filter with the tungsten needle.
They were then transferred to a culture well containing a serum-free medium
(DMEM F12, Sigma) supplemented with 1% ascorbic acid and cultured as a
Trowell's tissue culture, as described in Brunet et al. (1993) for 24 h at 37°C and
5% CO2 (which chronologically corresponds to stage HH23). Finally, the
explants were fixed in Carnoy, embedded in paraffin and processed for
histological sectioning.
For the different sets of experiments, cultures were made only in a serum-
free medium (400 μl per dish) as negative controls, or alternatively they were
supplemented with the following: (1) E-CSF from H.H. 25 chick embryos at 1/
7 v/v, as a positive control; (2) E-CSF + 2 μl of FGF2 antibody, diluted 1/100
(Sigma F-3393), to gauge the effect of the specific immunodeprivation of FGF2
in the E-CSF; (3) E-CSF + 2 μl of FGF2 antibody diluted 1/100 (Sigma F3393),
previously blocked with FGF2 at a 1/10 ratio (human recombinant Sigma
F0291-25UG), to assess the blocking capacity of FGF2's biological activity by
the FGF2 antibody employed; (4) 60 ng of FGF2 (human recombinant, Sigma
F0291-25UG) in 400 μl culture medium in order to confirm the effect of this
isolated factor; and (5) E-CSF + 2 μl of NGF antibody (Sigma N-6655) at 1/100
dilution, to discard any unspecific effects of the antibody added to the culture
medium. It is important to note that according to the supplier, both antibodies
block the biological activity of the recognized molecule. Occasionally we
carried out neuroepithelial explants cultured with a medium previously
conditioned by notochord. This took place as follows: fragments of cephalic
notochord from 25 H.H. stage chick embryo were dissected with tungsten
needles under microscope. Culture plates with 400 μl of specific medium
(DMEM F12, supplemented with 1% ascorbic acid), plus 3 fragments of
notochord per dish, were cultured for 24 h under the conditions explained above;
after the notochord fragments were removed, use was made of the specific
medium for neuroepithelium culture already described. Occasionally we did
cultures with a notochord-conditioned medium + FGF2 antibody (2 μl of FGF2
antibody, diluted 1/100) to verify that the effect of the conditioned medium is
due to the presence of this factor.
In ovo mesencephalic cavity microinjection
Chick embryos at HH20 were microinjected in ovo into the brain cavity,
with 400 nl of the same antibodies to FGF2, or alternatively to NGF, as those
employed in the in vitro study, both at 1/100 dilution, to compare the effects of
the immunodeprivation with respect to the in vitro experiments (see above).
Other embryos were microinjected with 400 nl of a solution of 50 ng of FGF2
ligand in 400 μl of Hank sterile, to compare with the experimental conditions
cited above. Controls were performed by microinjecting the solvent of the
antibodies, namely, PBS. Microinjection was performed with a glass
microneedle (10-μm inner diameter at the tip) connected to a microinjector
(Medical System PLI 100) into the mesencephalic cavity through a small
opening made in the extraembryonic membranes with a tungsten needle. The
microinjected embryos were reincubated in ovo for 24 h, and they were removed
from the egg at HH23.BrdU incorporation and tubulin immunostaining
In order to test the effect of the different experimental conditions on the
behavior of the neuroepithelial cells, we selected the main parameters, cell
replication and neurogenesis. Determination of BrdU incorporation into cell
nuclei was performed by adding BrdU to the culture medium at just 1 h from theend of the culture, at a final concentration of 5 μM (for the organotypic culture),
or by microinjecting 190 nl of BrdU in the outflow of the heart, once again at 1
h from the end of the culture (for in ovo experiments). Immediately after that, the
explants or embryos were fixed in Carnoy for 20 min, dehydrated in an alcohol
series, passed through xylene and embedded in paraffin. After transversal
sectioning of the tissues, they were deparaffinated, and BrdU was detected
following standard procedures. The sections were incubated in a solution
containing a monoclonal antibody to BrdU (Dako) at 1/100 for 30 min. To detect
the primary antibody, the avidin–extravidin system conjugated to peroxidase
(mouse anti-rabbit 1/20 for 30 min and extravidin 1/20 for 10 min; Sigma) was
used and staining was undertaken with DAB. We visualized and photographed
the preparations using a Nikon microphot-FXA photomacroscope. A quantita-
tive analysis of nuclear BrdU incorporation was performed by counting the
number of BrdU-positive nuclei in 34 microscopic fields of 1400 μm2 with 5
samples from 5 different explants. The average of each condition and the
standard error were plotted, and their significance was tested by a two-tailed
Student's t test.
We detected neuronal differentiation by β3-tubulin expression. After
treatment, the explants or the embryos maintained in ovo from different
experimental conditions were fixed in Carnoy and processed as described below
for histological study. Sections were blocked in 1% BSA in PBS and
subsequently incubated in a solution containing a monoclonal anti-tubulin
antibody at 1/500 (BAbCO), and, after extensive washes, they were incubated
with a solution containing an anti-mouse antibody conjugated to FITC at 1/64
(Sigma) for 1 h at room temperature. In order to facilitate identification of the
β3-tubulin-positive cells, we used single plane images obtained by confocal
laser microscopy in which cells showing a negative nucleus surrounded by a
labeled cytoplasm were deemed positive (see Fig. 2G).
A quantitative analysis of β3-tubulin expressing cells in vitro and in ovo was
performed by counting the number of neuroepithelial cells with immunostained
cytoplasm in 20 microscopic fields of 1900 μm2 from at least 4 different
samples. In the whole of the analysis, the average of each condition and the
standard error were plotted, and their significance was tested by a two-tailed
Student's t test.TUNEL assay
In order to rule out the possibility of the influence of the E-CSF FGF2 on
replication and neurogenesis in the neuroepithelial explants being the result
of a non-specific effect on cell survival, we assessed apoptosis by means of
the TUNEL technique on paraffin sections from formalin-fixed explants.
Apoptotic cells were detected using the Apoptosis Detection System
Fluorescein Kit (Promega) following the manufacture's instructions.
Visualization was made with a confocal microscope (Zeiss LSM-310). We
performed quantitative analysis by counting the number of stained nuclei of
neuroepithelial cells in 20 microscopic fields of 1900 μm2 from at least 4
different samples. In the whole of the analysis, the average of each condition
and the standard error were plotted and their significance was tested by a
two-tailed Student's t test.PC12 cells in vitro culture
In order to evaluate the capacity of our chosen anti-FGF2 antibody to block
the biological activity of FGF2, we conducted a biological assay on in vitro
cultured PC12 cells.
PC12 (8ATCC-CRL-1721) cells were cultured in DMEM + 6% horse
serum + 6% fetal bovine serum + 1% glutamin + 1% penicillin/streptomycin, in
a 5% CO2 atmosphere for 5 days, with a supplement of 100 μg/ml FGF2 (Sigma
F0291-25UG) or of the same amount of FGF2 blocked with 1.5 μl at 1/200
dilution of the anti-FGF2 antibody (Sigma F3393). For cell identification βIII
tubulin immunostaining was performed as described previously and revealed
with DAB. An evaluation of the effect of the FGF2 ligand was carried out by
establishing the percentage of cells emitting neurites which doubled the diameter
length of the cell body with respect to all the cells. The average of each condition
and the standard error were plotted, and their significance was tested by a two-
tailed Student's t test.
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Western blot analysis
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed under
denaturing conditions according to the method of Laemmli (1979), with a
Miniprotean II electrophoresis system (BioRad). Molecular mass standards of
high and low range (BioRad) were also used. SDS-PAGE was performed in a
discontinuous buffer system for 30 min at 200 V.
For 2D gel electrophoresis. The first dimension was run in a strip of 24 cm,
pH 7–11 (Amersham Bioscience), in the IPGPhor system, within a gradient
from 50 to 8000 V (accumulated voltage: 96,000 V/h). The second dimension
was run in a 24 × 21 cm, 12,5% acrylamide (50% de Duracryl) gel electro-
phoresis by using the Ettan Dalt II system (AmershamBioscience), at 3 w/gel for
30 min, followed by 19 w/gel for 4 h.
For Western blot analysis, proteins were electrotransferred from the
electrophoresis gel to nitrocellulose membrane (Trans-Blot Transfer Medium,
BioRad), for 1 h at 100 V (for SDS-PAGE) or overnight at 17 V (for 2D gel
electrophoresis), using a basic transfer buffer following standard protocols. The
immunoblotting was developed either with Opti-4CN (Sigma) or chemilumi-
nescence (Biological Industries) on an X-ray film.
With a view to determining whether FGF2 is capable of passing from the
embryonic fluid to the E-CSF, we conducted a Western blot SDS-PAGE of
aliquots of 50 μl E-CSF from embryos at developmental stage HH25, 5 μl of a
solution of 100 ng/μl of commercial FGF2 (Sigma F5542) linked to FITC, as we
describe later or 5 μl of a solution of 100 ng/μl of glutathione-S-transferase–
alcohol–dehydrogenase (GST-Adh) linked to FITC, as described below.
Detection was made with antibody rabbit anti-FGF2 (Sigma F3393, 1/2000),
mouse anti-GST (kindly provided by N. Cols, Dept. of Genetics, U. of
Barcelona, Spain) 1/2000 or mouse anti-FITC (Sigma F5636) 1/2000 and
subsequently with a secondary antibody anti-rabbit or anti-mouse IgG (Sigma)
conjugated to peroxidase.
In order to rule out crossed reactions with other ligands, we performed a
Western blot SDS-PAGE of aliquots of 0.5 μl of different solutions (100 μg/μl):
EGF (Sigma, E6135), FGF-1 (Sigma, F5542), FGF2 (Sigma, F0291-25UG) and
FGF8 (Sigma, F1802), which were exposed to the anti-FGF2 antibody (Sigma,
F3393).
The presence of different isoforms of FGF2 in the E-CSF, embryonic serum
and notochord-conditioned medium, were detected by a Western blot of
bidimensional electrophoresis of E-CSF (250 μl) from 25 H.H. stage chick
embryos, 150 μl of embryonic serum from 25 H.H. stage chick embryos and
250 μl notochord conditioned culture medium (see below). Immunostaining
was with anti-FGF2 antibody (Sigma F3393) or anti-FGF2 antibody previously
incubated with FGF2 factor (Sigma F0291-25UG) at 1/10 ratio.
FITC coupling, microinjection and detection
Commercial FGF2 stabilized with albumin (human recombinant, Sigma
F0291-25UG) and a glutathione-S-transferase–alcohol–dehydrogenase (GST-
Adh) fusion protein were coupled to fluorescein isothiocyanate Isomer I (FITC,
Sigma). The GST-Adh fusion protein (kindly provided by N. Cols, Dept. of
Genetics, U. of Barcelona, Spain) was a recombinant protein with a molecular
mass of 38 kDa made from the recombination of the Schistosoma japonicum
GST and the Drosophila lebanonensis Adh genes. This recombinant protein was
used as a negative control as its amino acidic sequence did not show similarity
with any known chick protein.
The coupling with FITC was performed as described in Harlow and Lane
(1988) for antibodies. The unbounded dye was separated by gel filtration
(Sephacryl S-200, Pharmacia). The final ratio of absorbance at 495/280 nm for
the conjugated proteins was 0.81 for FGF2-FITC and 0.93 for GST-Adh-FITC.
500 nl of both conjugates at 0.2 mg/ml in NaCl physiological solution (9 g/l)
were microinjected into the outflow of the heart of H.H.22 chick embryos with a
glass microneedle (10-μm inner diameter at the tip) connected to a microinjector
(Medical System PLI 100), and the E-CSF from these embryos was recovered
after 24 h of in ovo development (i.e., HH25), as described above. To identify
the conjugates, FGF2-FITC and GST-Adh-FITC in the E-CSF of the
microinjected embryos, this fluid was run in a 12% SDS-PAGE and transferred
to a nitrocellulose membrane; FGF-2, GSH and FITC were detected by Western
blot immunolabeling as described in the previous section.RNA in situ hybridization and semiquantitative PCR analysis
RNA in situ hybridization was performed as described by Bueno et al.
(1996) for one probe using single-stranded digoxigenin–UTP-labeled
(Boehringer Mannheim) antisense riboprobes. Fgf2 riboprobe (fgf2-288;
Savage and Fallon, 1995; EcoRI digestion and T3 transcription), recognizing
all known fgf2 isoforms, was used. Hybridization was developed with NBT/
BCIP according to standard protocols for 6 to 36 h, depending on the embryo
developmental stage. To avoid the trapping of reagents in the cephalic
cavities, embryos older than HH18 were dissected in two symmetrical halves
prior to whole-mount hybridization.
After probe detection, embryos were embedded in paraffin, sectioned at
10 μm and mounted on gelatine-coated slides. Photomicrographs were taken
using a Stemi V6 stereomicroscope (Zeiss) and an Axiophot microscope
(Zeiss). Images were digitalized by capturing them with a CCD Coopix 995
camera (Nikon), and they were assembled by using Photoshop software.
PCR analysis was made on several different embryonic tissues, dissected
under the control of a dissecting microscope. The total mRNAwas purified by
using the RNeasy Mini Kit for RNA extraction (Qiagen). Primers used for FGF2
PCR amplification were as follows: forward, 5′ctgcagcttcaagcagaag3′, which
amplifies all known isoforms; forward, 5′gcttccagccagccgaggg3′, which
amplifies the Low Molecular Isoforms (LMW) isoform; forward, 5′
tggacggccgcggcaggg3′ and 5′gagcatcaccacgctgcc3′, which amplify different
High Molecular Isoforms (HMW); and reverse, 5′, for all amplification
reactions. Primers used for actin controls were the following: forward, 5′
tggatgatgatattgctgc3′; and reverse, 5′atcttctccatatcatccc3′. A regime consisting
of 94°C for 2 min (1 cycle), 94°C for 1 min–45°C for 30 s–72°C for 45 s (35
cycles), followed by a single terminal extension step (72 C for 5 min) on an
Eppendorf Mastercycler was used for all primer sets. Actin was used as an
internal control for semiquantitative comparison. Sample dissection was
independently performed twice, and each PCR experiment was performed
with 4–5 separate RNA-cDNA collections.Results
FGF2 is present in the chick E-CSF
First of all, in order to establish the basis for our theory
that FGF2 acts on neuroepithelial cells from the E-CSF, it is
necessary to test whether FGF2 is present in the E-CSF.
Western blot analysis of E-CSF after 2D gel electrophoresis
was performed (Fig. 1A) and the chemiluminescence of the
Western blot showed the presence of immunoreactive spots
located between pI 10 and pI 10.5, as expected for basic FGF.
Four immunoreactive spots were clustered at a molecular
mass between 17 and 24 kDa, and one other spot showed a
molecular mass of approximately 34 kDa, as expected for the
different low molecular weight (LMW) and high molecular
weight (HMW) FGF2 isoforms cited in the literature. To
ensure specificity in FGF2 ligand recognition by the antibody
we employed, we conducted two complementary experiments:
first, we checked (Fig. 1B) that previous exposure of this
antibody to FGF2 eliminated its capacity to mark all the spots
in the E-CSF; secondly, we performed a monodimensional
Western blot with anti-FGF2 antibody on different growth
factors (Fig 1D), which enabled us to verify that our anti-
FGF2 antibody showed no crossed reactions with other
members of the family of FGFs (particularly, FGF1 and
FGF8) or other factors such as the EGF. These experiments
allow us to assert that at the H.H. 25 developmental stage, E-
CSF contains distinct FGF2 isoforms.
Fig. 1. Western blot analysis from a 2D gel electrophoresis (A, B and C) developed with chemiluminescence to increase sensibility. (A) E-CSF from chick embryos
at stage HH25, labeled with monoclonal antiFGF2 antibody showing the presence of diverse isoforms of the FGF2 in E-CSF. (B) E-CSF from chick embryos at stage
H.H. 25, labeled with monoclonal antiFGF2 antibody preabsorbed with FGF2 ligand showing the absence of spots labeled in panel A, corroborating the specificity
of the label. (C) Embryonic serum from chick embryos at stage HH25, labeled with monoclonal antiFGF2 antibody showing the presence of diverse isoforms of the
FGF2 in embryonic serum. (D) Western blot analysis from a SDS-PAGE electrophoresis of several growth factors (indicated at the bottom of the image) labeled with
monoclonal antiFGF2 antibody showing no cross-reaction except with FGF2. Molecular weight is indicated on the left side and the isoelectric point (pI) appears at
the bottom of the images. The red squares in panel A delimit the positive spots for FGF2 of the E-CSF in the different ranges of molecular weight.
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the behavior of neuroepithelial stem cells
To check whether E-CSF is an alternative source of FGF2
capable of influencing neuroectodermal cell proliferation and
differentiation, and thus whether it is one of the active compo-
nents of this fluid, responsible at least in part for its previously
described trophic role, we performed two experiments.
Firstly, mesencephalic organotypic cultures were made in
several different conditions (Fig. 2). As a positive control, we
used explants cultured with whole E-CSF supplementedFig. 2. Analysis of neuroepithelial cell proliferation and neuronal differentiation in tran
HH20 and cultured in vitro for 24 h (i.e., to a developmental stage equivalent to HH2
nuclei are shown in brown. Neuronal differentiation has been monitored by immunos
β-tubulin-positive cells (G) shows the identifying criteria of the β3-tubulin-positive c
The different experimental conditions are as follows: (A) Explants cultured in serum
medium with no supplement; note an intense decrease in replication and neurog
supplemented with E-CSF and immunodeprived with an antibody to FGF2; note t
replication and neurogenesis. (D) Explants cultured in serum-free medium supplemen
no reduction in replication and neurogenesis is observed showing that FGF2 antibody
Explants cultured in serum-free medium supplemented with commercial FGF2 human
cultured in serum-free medium supplemented with E-CSF and immunodeprived with
neurogenesis in neuroepithelial cells. Quantification of BrdU incorporation (H) and q
correspond with those of the different experimental conditions. Standard error is sho
two-tailed Student's t test. Image J corresponds to a PC12 cells in vitro culture showin
an FGF2 antibody was added to the culture media. Quantification data are expressed in
L shows apoptotic cells detected by TUNEL method in mesencephalic explants. No
increase of apoptotic cells in FGF2-supplemented and non-supplemented explants. Th
M shows the quantification of apoptosis data in different experimental condition (in
significantly (P < 0.001) from controls, according to the two-tailed Student's t test.medium (Fig. 2A), and, as a negative control, we used explants
cultured only in a chemically defined medium (Fig. 2B). As we
described in the introduction, the presence of E-CSF in the
culture, medium is capable of activating replication and
neurogenesis in neuroepithelial cells. To test whether the
FGF2 contained within the E-CSF was involved in regulating
the behavior of neuroepithelial stem cells, mesencephalic
explants were cultured with E-CSF in which this ligand had
been specifically immunodeprived by the previous adding of
the monoclonal antibody to FGF2. In these organotypic
cultures, both BrdU incorporation and β3-tubulin expressionsversal histological sections of chick mesencephalic neuroectoderm explanted at
3). BrdU incorporation has been monitored with a specific antibody and labeled
taining with a commercial antibody to β-tubulin, a high magnification image of
ells which show a negative nucleus (red line) surrounded by a labeled cytoplasm.
-free medium supplemented with E-CSF. (B) Explants cultured in serum-free
enesis with respect to panel A. (C) Explants cultured in serum-free medium
hat immunoblocking of FGF2 in E-CSF also leads to an intense reduction in
ted with E-CSF and with antibody to FGF2 previously saturated by FGF2 ligand;
action (see C) is due to specific blocking of E-CSF FGF2 biological activity. (E)
recombinant; note the recuperation of replication and neurogenesis. (F) Explants
a commercial antibody to NGF; this condition has no effect on replication and
uantification of neuronal differentiation (I). The letters at the bottom of each bar
wn. *Values that differ significantly (P < 0.001) from controls, according to the
g the inhibition of the neuritic growth induction (arrows) by FGF2 ligand, when
image K; experimental conditions are indicated at the bottom of each bar. Image
te the low number of apoptotic cells in E-CSF supplemented explants and the
is demonstrates that FGF2 is not involved in neuroepithelial cell survival. Image
dicated at the bottom of each bar). Standard error is shown. *Values that differ
Scale bar in all images: 50 μm.
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respectively (Figs. 2C, H and I), with respect to the positive
control. Interestingly, the number of proliferating and differen-
tiating cells in explants treated with E-CSF plus the anti-FGF2
antibody was similar to that in negative controls, suggesting that
the FGF2 present in E-CSF plays a key role in E-CSF biological
activity. In order to verify that anti-FGF2 antibody is capable of
selectively blocking the biological activity of the FGF2 ligand,we repeated the previous experiment but adding to the E-CSF
supplemented medium anti-FGF2 antibody which had been
exposed beforehand to the exogenous FGF2 ligand (Fig. 2D);
the results showed the recuperation of proliferation and
neurogenesis values similar to those of the controls (Figs. 2H
and I). Similarly, and so as to verify the specificity of the
blocking of FGF2 biological activity by the anti-FGF2 antibody
we employed, we performed complementary experiments with
408 C. Martín et al. / Developmental Biology 297 (2006) 402–416in vitro cultured PC12 cells, as shown in Fig. 2J; the PC12 cells
underwent differentiation in the presence of FGF2, triggering
the emission of neurites, a process almost totally inhibited when
the anti-FGF2 antibody was added to the FGF2-supplemented
culture medium (Fig. 2K). These data allow us to affirm that the
action of the anti-FGF2 antibody is attributable to its capacity to
block the biological activity of the FGF2 ligand.
Subsequently, and to corroborate these results, mesence-
phalic neuroepithelial explants were cultured in serum-free
medium supplemented with commercial FGF2 (Fig. 2E). The
rate of BrdU incorporation and neuronal differentiation reached
elevated values (Figs. 2H and I), albeit not so high as those of
the positive controls; what is more, although the differences
observed were statistically significant, the number of BrdU and
β3-tubulin-positive cells was nearly double that of both
explants cultured with the medium supplemented with E-CSF
and immunodeprived with anti-FGF2 antibody, and negative
controls (Figs. 2B and C).
To discard any unspecific effect due to the addition of the
antibody to the culture medium, mesencephalic neuroepithelial
explants were cultured in E-CSF supplemented medium to
which a commercial antibody to NGF was added (Fig. 2F). We
used this antibody as a negative control since it has been
reported that NGF does not act on brain development at these
developmental stages (Ford-Perriss et al., 2001; Panchision and
McKay, 2002). In these organotypic cultures, the rate of BrdU
incorporation and neuronal differentiation reached the same
level as in positive controls (Figs. 2H and I).
Finally, to rule out the possibility of the influence of FGF2
on replication and differentiation of the neuroepithelial cells
being due to an indirect action on cell survival, we conducted
a study of the presence of apoptotic cells on the in vitro
cultured neuroepithelial explants. The results demonstrate
(Figs. 2L and M) that the addition of FGF2 to the culture
medium does not significantly reduce the number of apoptotic
cells in respect of the explants cultured in a defined medium;
however, the presence of apoptotic cells was scarce in the
explants with E-CSF added to the culture medium. These data
indicate that FGF2 does not have a direct influence on cell
survival, and that this might be controlled by other factors
present in the E-CSF.
Secondly, to check whether FGF2 from the E-CSF is able
to influence neuroectoderm proliferation and differentiation in
vivo, 20 H.H. chick embryos were microinjected in the brain
cavity with the monoclonal antibody to FGF2 to selectively
block this ligand in vivo, with the FGF2 ligand and
alternatively with a commercial antibody to NGF as a control
for immunodeprivation (see above); following 24 h culture,
no macroscopic malformations were appreciated in the
embryonic brain under any experimental condition. Embryos
microinjected with the antibody to FGF2 showed a reduction
in the number of BrdU-positive nuclei to approximately 40%
with respect to the controls, a statistically significant finding
(Figs. 3A, B and J); however, the embryos microinjected with
the FGF2 ligand and antibody to NGF did not show any
significant variation in the number of BrdU-positive nuclei
(Figs. 3C, D and J).With respect to neurogenesis, embryos microinjected with
the antibody to FGF2 showed a reduction in the number of β3-
tubulin-immunoreactive cells to approximately 50% with
respect to the controls, again statistically significant (Figs. 3E,
F and K); yet embryos microinjected with FGF2 ligand
presented a significant reduction with respect to the controls,
but their values were higher tan those of the embryos
microinjected with the anti-FGF2 antibody (Figs. 3G and K).
The antibody to NGF did not show any significant reduction
in the number of β3-tubulin-immunoreactive cells (Figs. 3H
and K).
Finally, to test whether FGF2 immunodeprivation affects
only the ligand contained within the E-CSF or also the ligand
contained within the neuroepithelial tissue, the distribution of
the antiFGF2 antibody microinjected into the brain cavity was
analyzed 24 h after injection. As shown in Fig. 3I, the
microinjected antibody to FGF2 was confined within the brain
cavity, suggesting that FGF2 immunodeprivation only affects
the ligand contained within the E-CSF.
These data indicate that, in chick embryos, the FGF2
contained within E-CSF exerts a mitogenic and differentiating
role on the neuroectodermal cells both in vitro and in vivo.
Origin of E-CSF FGF2
To throw light on the embryological origin of the FGF2
detected within the chick E-CSF, i.e., to determine whether the
neuroectoderm is the source of the FGF2 contained within E-
CSF, or whether, instead, it comes at least in part from any other
embryonic tissue or organ, we carried out a study of fgf2 mRNA
expression by in situ hybridization at developmental stages
HH13 to HH27, and semiquantitative PCR analyses of different
embryonic tissues of H.H.25 chick embryos were performed.
Fgf2 in situ hybridization analysis showed that none of the
known isoforms of this gene could be clearly detected at any site
on the neuroectoderm in all developmental stages analyzed, i.e.,
from HH13 to 27 (Figs. 4A, D, G and data not shown). It is
important to note that in some in situ hybridizations, a diffuse
NBT/BCIP precipitate in the neuroepithelium was observed
(not shown), although this was hard to interpret as a positive
hybridization.
Despite this apparent low level of fgf2 expression in the
neuroectoderm, this gene was clearly expressed at other distinct
sites of interest to us. At HH18, fgf2 started to be expressed in
the notochord, the rope-shaped structure that it is known to be
responsible for the secretion of distinct signaling molecules
(Figs. 4A, B and C). Fgf2 expression in the notochord was
detected from H.H.18 to H.H.27. The intensity of this
structure's staining increased notably with growth, and at
stage 23 H.H. it was much greater than that of other structures
(Figs. 4D, E and F). Fgf2 expression was also detected in the
mesonephros from H.H.13 to H.H. 27 (Figs. 4C, F, and data not
shown), and in a portion of the liver primordium, an organ that
is known to supply different molecules and cells to the
embryonic serum, in a location close to the ductus venosus,
from HH22 to 27 (Fig. 4F, and data not shown). In addition,
Fgf2 expression was detected in other embryonic sites (data not
Fig. 3. Transversal histological sections and quantitative analysis of BrdU incorporation and neuronal differentiation in the mesencephalic neuroectoderm of embryos
at HH23, maintained in ovo 24 h after microinjection in the brain cavity. BrdU incorporation has been monitored with a specific antibody and is shown in brown.
Neuronal differentiation has been monitored by immunostaining with a commercial antibody to β-tubulin and is shown in green fluorescence. Experimental conditions
are indicated at the top of the cultures or at the bottom of each bar plot. (A and E) In vivo control microinjected with Hank saline, (B and F) microinjection of anti-FGF2
antibody; (C and G) microinjection of FGF2 ligand and (D and H) microinjection of anti-NGF antibody. Note the decrease in BrdU incorporation and neuronal
differentiation in the neuroepithelium of embryos after the immunoblocking of FGF2 in the E-CSF (B and F), while FGF2 ligand microinjection (C and G) or
microinjection of another antibody does not produce any alteration. In panel G, it is shown as the anti-FGF2 antibody microinjected into the midbrain cavity, detected
by immunolabeling with a secondary antibody marked with peroxidase; it is confined to the cavity without penetrating the neuroepithelium. Quantification of BrdU
incorporation (J) and quantification of neuronal differentiation (K) Standard error is shown. *Values that differ significantly (P < 0.001) from controls, according to the
two-tailed Student's t test. Scale bar in panels A, B, C and D: 30 μm. Scale bar in panels E, F, G and H: 50 μm.
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development, from HH18 to 27, in the developing heart, in the
foregut, and in the limb bud.
Due to the presence of very faint NBT/BCIP precipitate
in the neuroectoderm in some hybridizations, and as other
authors had reported the expression of fgf2 in some
neuroectodermal tissues, such as the mesencephalon and
the spinal cord, when radiolabeled riboprobes were used, a
semiquantitative PCR analysis of different portions of the
neuroectoderm (i.e., mesencephalon and spinal cord) was
performed for different fgf2 isoforms. The result was then
compared with a semiquantitative PCR analysis of the
tissues where fgf2 expression was clearly detected in our insitu hybridizations (i.e., the notochord and the liver and
mesonephros area). This analysis clearly showed that
different LMW and HMW fgf2 isoforms were expressed
in the notochord and in the liver and mesonephros area
(Fig. 4H), as well as in the neuroectodermal tissue of the
mesencephalon and the spinal cord. The relative level of
fgf2 expression in the tissues analyzed with respect to actin
control detected by this semiquantitative PCR amplification
allows us to suggest that, in chick embryos, fgf2 is
expressed at much higher levels in the notochord and in the
liver and mesonephros area than in the neuroectoderm,
which is in agreement with the results obtained by in situ
hybridization.
Fig. 4. Fgf2 in situ hybridization on whole-mount chick embryos at different developmental stages. (A) Whole-mount embryo at H.H.18. (B) Transversal section of the
embryo depicted in A at the level of the rhombencephalon and otic vesicle. (C) transversal section of the embryo depicted in panel A at the spinal cord level. (D)
Whole-mount embryo at H.H.23. (E) Transversal section of the embryo depicted in panel D at the level of the rhombencephalon and first branchial arch. (F)
Transversal section of the embryo depicted in panel D at the spinal cord level. (G) Sagittal section of an embryo at H.H. 23 stage showing the brain vesicles. Note the
scarce or non-existent mRNA expression at different levels of neuroepithelium and the increase in mRNA expression of fgf2, with development particularly in the
notochord, mesonephros and ductus venosus of the hepatic primordium. (G) Fgf2 mRNA semiquantitative PCR analysis on several different embryonic tissues:
mesencephalon, spinal cord, notochord, and liver plus mesonephros, in order to show quantitative differences in the levels of fgf2 mRNA expression among the
different tissues. Actin mRNA expression has been included as a reference parameter. Abbreviations: ba, branchial arch; dv, ductus venosus; e, eye; fg, foregut; pr,
prosencephalon; di, diencephalon; me, mesencephalon; rh, rhombencephalon; mn, mesonephros; nt, notochord; ov, otic vesicle; LMW, low molecular weight isoform;
HMW, high molecular weight isoforms.
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with a chemically defined medium, together with those of
immunodeprivation of FGF2 in the E-CSF, both in vitro and in
vivo, and also the low fgf2 expression detected in the
neuroepithelium as compared with other embryonic tissues
and organs, indicate that neuroepithelial FGF2 production is not
able to self-induce a normal level of neuroepithelial cell
proliferation and neurogenesis; in addition, these findings
suggest that the FGF2 contained within the E-CSF may be
produced at least in part by extraneural tissues and then shifted
into the E-CSF via the embryonic serum. To support this
hypothesis, we contemplate three conditions. (1) The extra-
neural tissues which express fgf2 should be capable of liberating
soluble forms of FGF2. (2) FGF2 should be present in the
embryonal serum. (3) FGF2 should be able to pass from the
serum to the E-CSF via the neuroepithelium.In order to test the first point, we made cultures of fragments
of cephalic notochord from stage 25 H.H. chick embryo over a
period of 24 h in a defined medium. AWestern blot analysis of
this medium (Fig. 5A) revealed the existence of diverse
isoforms of FGF2 coinciding with the normal molecular
weights, thus confirming that at least one of the tissues which
expressed FGF2 is capable of liberating this as a soluble factor.
In addition, and with the aim of checking whether this liberated
FGF2 is able to directly influence the behavior of the
neuroepithelial cells, cultures were made of neuroepithelial
explants in a notochord-conditioned medium. Results demon-
strated that the defined medium conditioned with notochord is
able to activate neuroepithelial cell replication up to three times
more than the value for the explants cultured in a medium not
conditioned with notochord (Figs. 5B, D and H) and induce a
high degree of neurogenic activity in the neuroepithelial cells,
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non-conditioned medium (Figs. 5 C, E and I). Both effects
drastically diminished when the FGF2 antibody was added to
the conditioned medium (Figs. 5 F, G, H and I), as a result of
which we conclude that this is due to the presence of FGF2.
As regards the second point, we performed a Western blot
analysis of embryonic serum and E-CSF with an antibody toFGF2 after a bidimensional electrophoresis. This analysis
showed the presence of 34, 24 and 17 kDa antiFGF2-im-
munoreactive spots in both the E-CSF and the embryonic serum
(Figs. 1A and C).
To test the third point, commercial FGF2 was coupled to
FITC and microinjected into the outflow of heart of chick
embryos at HH24. The E-CSF from these embryos was
recovered at HH27 and run in a SDS-PAGE.
Commercial FGF2 coupled to FITC before injection appears
as a 34-kDa band on the Western blot recognized by both the
anti-FGF2 antibody (Fig. 6A) and the anti-FITC antibody (Fig.
6B), which indicates that the FGF2-FITC union is stable.
In Fig. 6B appears another band of 66 kDa which
corresponds to the bovine seroalbumin bound to FITC, used
by the suppliers to stabilize the FGF2 ligand.
Twenty-four hours following intravascular microinjection of
FGF2-FITC, the Western blot of the E-CSF revealed a band of
34 kDa labeled with both the anti-FGF2 antibody (Fig. 6C) and
the anti-FITC antibody (Fig. 6D). This indicates that the FGF2-
FITC injected in the vascular system of the embryo passes to the
E-CSF, while a protein of higher MW (albumin) does not,
suggesting that certain proteins could pass from the embryonic
serum to the E-CSF in accordance with their molecular weight.
To analyze the effect of protein size on this favored uptake, a
fusion protein not existent in chick but with a similar molecular
mass to FGF2 was also coupled to FITC and microinjected into
the outflow of heart of chick embryos at H.H.24 (GST-Adh,
predicted MW = 38 kDa). Preinjection solution of GST/Adh-
FITC was detected by Western blot as a band of 38 kDa both
with the anti-GST antibody (Fig. 6E), and with the anti-FITC
antibody (Fig. 6F). This indicates that the GST/Adh-FITC
union was stable. Twenty-four hours after intravascular
microinjection of the GST/Adh-FITC protein, the Western
blot of the E-CSF showed no band with any of the two
antibodies we employed (Figs. 6 G and H), suggesting that E-
CSF uptake of this fusion protein from the embryonic serum
was not favored.Fig. 5. (A) Western blot analysis of defined medium conditioned with notochord
developed with monoclonal antiFGF2 antibody from 2D gel electrophoresis,
chemiluminescence was used to increase sensibility. Molecular mass is indicated
on the left-hand side, and the isoelectric point (pI) appears at the bottom of the
image. Analysis of neuroepithelial cell proliferation and neuronal differentiation
in transversal histological sections of chick mesencephalic neuroectoderm
explanted at H.H.20 and cultured in vitro for 24 h (i.e., to a developmental stage
equivalent to H.H.23). BrdU incorporation has been monitored with a specific
antibody and labeled nuclei are shown in brown. Neuronal differentiation has
been monitored by immunostaining with a commercial antibody to β-tubulin
and positive cytoplasms are shown as green fluorescence. The different
experimental conditions are as follows: (B and C) Explants cultured in a defined
medium conditioned with notochord. (D and E) Controls explants cultured in a
defined medium without supplement. (F and G) Explants cultured in a defined
medium conditioned with notochord plus FGF2 antibody. BrdU-positive cells
quantification (F) and neurogenesis quantification (G) has been plotted and
experimental conditions are indicated at the bottom of each bar. Note the
increase in proliferation and neurogenesis induced by the notochord-conditioned
medium. Standard error is shown. Values that differ significantly (*P < 0.05,
**P < 0.001) from controls, according to the two-tailed student's t test. Scale bar
in panels B and D: 30 μm. Scale bar in panels C and E: 50 μm.
Fig. 6. Western blot analysis from SDS-PAGE electrophoresis of commercial FGF2 ligand and glutathione-S-transferase-alcohol–dehydrogenase linked to FITC. Both
molecules were immunolabeled by an antibody against to specific protein or with an antibody against FITC either in solution (preinjection) or in E-CSF 24 h. after
intravascular microinjection. The FGF2 antibody detected a 34-kDa band (A) and a similar band was also detected by the anti-FITC antibody (B) in FGF2 preinjection
solution, showing that FGF2-FITC linkage was successful. A 66-kDa band was recognized by anti-FITC antibody (B) which corresponds to seroalbumin used to
stabilize the commercial FGF2. After intravascular microinjection of FGF2-FITC a 34-kDa band was detected in E-CSF by both anti-FGF2 (C) and anti-FITC (D)
antibodies, showing that FGF2-FITC, passes via the neuroepithelium from the serum to the E-CSF; however, seroalbumin does not. GST-Adh-FITC protein was
labeled in preinjection solution by both, anti-GST (E) and anti-FITC (F) antibodies as a 38-kDa band, showing that the GST-Adh-FITC linkage was successful. After
intravascular microinjection of GST-Adh-FITC protein, no band was detected in E-CSF either by the anti-GST (G) or the anti-FITC (H) antibodies, showing that
proteins with a similar molecular weight to FGF2 does no pass from the serum to the E-CSF.
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incorporation from the embryonic serum to the E-CSF in chick
embryos, whereas other proteins of a similar molecular weight
are incapable of behaving in the same way.
Discussion
The results of our study demonstrate the following: (1)
different isoforms of FGF2 are present in the CSF and serum of
chick embryos in early stages of development; (2) in this species
the FGF2 in E-CSF is directly involved in both the in vivo and
in vitro proliferation and neural differentiation of neuroepithe-
lial cells; (3) neuroepithelial cells express low levels of fgf2
mRNA and the FGF2 from serum is incorporated into the E-
CSF, suggesting that some FGF2 contained within E-CSF may
have an extraneural origin.
FGF2 is an important active component of E-CSF
Embryonal CSF has a complex protein composition which
differs from that of the adult both in terms of quality and
quantity; also, it has been suggested that it might play diverse
biological roles during brain development (Birge et al., 1974;
Fielitz et al., 1984; Checiu et al., 1984; Dziegielewska et al.,
2000; Miyan et al., 2003; Gato et al., 2004; Parada et al.,
2005b). In this regard, we have recently demonstrated that E-
CSF exercises an important trophic effect in vitro on
neuroepithelial cells during early chick embryo development
(Gato et al., 2005), despite the fact that the molecules involved
are still to be identified. In this paper, we show that chick
embryo E-CSF contains different isoforms of FGF2 which
could influence the behavior of the neuroepithelial cells; this
factor is considered the main instrument involved in activating
replication and neurogenesis from neural stem cells (Vaccarino
et al., 1999b; Panchision and McKay, 2002). Flamme et al.(1919) and Ribatti et al. (1995), had previously described a
similar role of FGF-2 via a liquid medium on chick embryo
chorioallantoic fluid, in which it activates vasculogenesis of the
chorioallantoic membrane. In addition, the presence of FGF-2
or FGF2-like activity has been described in adult CSF, where it
has been attributed a role in neuronal survival and in
neurogenesis from stem cells (Bruni, 1998; Nicholson, 1999;
Reuss and von Bohlen und Halbach, 2003); also, alterations in
the concentration and/or bioavailability of this factor in CSF
have been cited in patients with neurodegenerative disorders
or brain injuries (Patterson et al., 1993; Tooyama, 1993;
Hanneken et al., 1995; Yosimoto et al., 1997; Stopa et al., 2001).
We have detected distinct isoforms of FGF2 (34 and between
17 and 24 kDa) in the E-CSF of chick embryos which coincide
with the molecular weights described for this factor in CNS
(Reuss and von Bohlen und Halbach, 2003). The presence of
these molecules in E-CSF suggests soluble forms of this factor,
and although it has been proposed that in the brain embryo the
LMW forms of FGF2 act according to a paracrine mechanism
while those of HMW follow an intracrine mechanism
(Vaccarino et al., 1999b; Reuss and von Bohlen und Halbach,
2003), our results show that such isoforms may also work as
soluble molecules from the E-CSF. Moreover, FGF2 is
considered a heparin binding growth factor, and it is known
that certain proteoglycans such as heparan sulphate (Ruoslahti
and Yamaguchi, 1991; Nurcombe et al., 1993; Guimond and
Turnbull, 1999; and Sperinde and Nugent, 2000) and
chondroitin sulphate (Milev et al., 1998) have a direct influence
on its level of biological activity, favoring extracellular
transportation, and protecting it from degradation by means of
proteases, as well as helping to activate receptors. In this regard,
we have previously demonstrated the presence of diverse
sulphated proteoglycans in E-CSF (Gato et al., 1993; (Alonso et
al., 1998; Parada et al., 2005a), which suggests that the activity
of the FGF2 from the E-CSF could have complex regulating
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play a role.
These results suggest that an extraneuroepithelial source of
FGF2 might participate in regulating the behavior of neural
stem cells during the development of the embryo.
The FGF2 in E-CSF is involved in controlling neuroepithelial
replication and neurogenesis
In this study, we show that selective in vitro and in vivo
immunoblocking of the biological activity of the FGF2 in E-
CSF at early stages of development, notably reduces the trophic
effect of this fluid on the neuroepithelium which we recently
described (Gato et al., 2005), thereby significantly diminishing
mitotic activity and neurogenesis. However, our neuroepithelial
cell apoptotic study show that FGF2 does not play a key role in
cell survival, which could be controlled by other E-CSF factors.
In order to demonstrate that these effects are not due to an
immunoblocking of FGF2 biological activity in the neuroe-
pithelium itself, we have verified that the anti-FGF2 antibody
injected into the embryonal brain cavity does not penetrate the
neuroepithelial tissue but remains confined to the cavity of the
brain vesicles; this ensures the specificity of the antibody acting
on the FGF2 of E-CSF. In this way, we show that, in vitro,
disruption of replication and neurogenesis in the neuroepithe-
lium cultured in a defined medium is to a large extent
compensated for by the exogenous addition of FGF2. These
data suggest, therefore, that the FGF2 is a key component in the
trophic action of E-CSF on neuroepithelial stem cells.
In fact, FGF2 is considered a trophic factor involved in the
behavior of CNS stem cells, on which it exerts a strong
mitogenic and neurogenetic influence both in embryonal and
adult stages. It has been demonstrated that during the
development of the embryo (above all, in in vitro studies)
FGF2 has an intense mitogenic effect on neuroepithelial stem
cells and is capable of triggering neurogenesis (Murphy et al.,
1990; Tropepe et al., 1999; Vaccarino et al., 1999b; Raballo et
al., 2000; Panchision and McKay, 2002; Reuss and von
Bohlen und Halbach, 2003). In this regard, our findings
provide experimental evidence of these actions of FGF2 in
vivo on the neuroepithelial cells of chick embryos in early
stages of development, this accord with the intense reduction
in replication and neurogenesis described in the neuroepithe-
lium of FGF2 knockout mice (Raballo et al., 2000). Despite
the references in these processes to other factors such as EGF
and IGF1 (Drago et al., 1991; Tropepe et al., 1999), the
general opinion is that during early developmental stages
neuroepithelial stem cell proliferation and differentiation
mainly depend on FGF2. Similar effects have been described
for FGF2 on neural progenitor cells in postnatal and adult
stages (Tao et al., 1996, 1997; Wagner et al., 1999; Cheng et
al., 2001), although it has also been attributed a role as a
neuroprotector, in the repair of CNS lesions (Patterson et al.,
1993; Yoshimura et al., 2003; Reuss and von Bohlen und
Halbach, 2003), and disruptions have been described of FGF2
levels in the cerebrospinal fluid among patients with
neurodegenerative disorders (Stopa et al., 2001).The existence of a specific spatio-temporal pattern of fgf2
expression in the neuroepithelium of rodent embryos has been
shown in various studies (Vaccarino et al., 1999a,b; Dono et
al., 1998; Dono, 2003). Our findings show that fgf2 mRNA
expression in the CNS of chick embryos detected by means of
in situ hybridization at the analyzed stages is much more
lower than that detected in other embryonic structures, such as
the notochord and the mesonephros. Such differences have
been confirmed by semiquantitative PCR, which allows us to
make a comparative estimation of the fgf2 expression levels.
In fact, fgf2 expression by both in situ hybridization and
immunochemistry on the neuroepithelium of avian embryos is
controversial because, despite most authors have shown a very
low fgf2 expression or not expression at all in the CNS (Han,
1997; Savage and Fallon, 1995, on chick embryos; and
Kalcheim and Neufeld, 1990, on quail embryos), other authors
have described the presence of FGF2 in the telencephalon and
mesencephalon of chick embryos at HH17 (Dono, 2003).
However, the lack of histological section in this latter report
makes very difficult to evaluate the tissular location and the
intensity of FGF2 immunochemistry. In this way, our data
support the idea that in chick embryos fgf2 exhibits a low
level of expression in the neuroepithelium, and thus, this
difference with respect to rodents suggests the existence of
phylogenetic variations.
The different members of the family of FGFs act via different
types of receptors, although it is reported (Tropepe et al., 1999)
that the action of FGF2 on the early development of the CNS is
mediated mainly by FGFr1 and 2. These receptors are expressed
differentially in the neuroepithelium of chick and rodent
embryos, with FGFr1 presenting a more ubiquitous pattern
than FGFr2 (Wilke et al., 1997; Walshe and Mason, 2000;
Trokovic et al., 2005); however, certain authors have described a
greater concentration of FGFr for both avian and rodent embryos
in those regions of the neuroepithelium which are close to the
ventricular cavities in contact with E-CSF (Heuer et al., 1990;
Raballo et al., 2000).
The coincidence in FGF2 expression and that of its
receptors in the neuroepithelium has led to a theory of
autocrine–paracrine behavior on the part of FGF2 during the
development of the CNS. However, previous studies we
carried out (Gato et al., 2005) have demonstrated that
mesencephalic neuroepithelia of chick embryos cultured in a
chemically defined medium without external supplements are
incapable of maintaining normal levels of proliferation and
neurogenesis during a short 24-h period. This indicates that
intrinsic factors in the developing brain are insufficient to
maintain normal levels of proliferation and neurogenesis,
suggesting that factors outside the neuroepithelium are
involved in regulating these processes; this coincides with
the findings of Drago et al. (1991) and Raballo et al. (2000),
in that an exogenous contribution of FGF2 is required in the
regulation of neuroepithelial cell behavior.
In this regard, our results show that in chick embryos E-
CSF is an exogenous source of FGF2, and the specific
immunoblocking of this factor's biological activity on E-CSF
considerably reduces both the in vivo and in vitro rate of
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FGF2 of E-CSF has a direct influence on the behavior of
neuroepithelial cells at early stages of development. These
findings are coherent with the apical positioning of the FGF2
and its receptors described by Raballo et al. (2000), who
suggest that these cells could incorporate FGF2 from the
cerebrospinal fluid itself.
The abovementioned data suggest the existence of two
simultaneous routes by which FGF2 acts on the neuroepithe-
lium during chick brain development: one of an autocrine–
paracrine mechanism within the neuroepithelium itself and the
other an exogenous source in E-CSF. One possible explana-
tion of this is given in the studies carried out by Qian et al.
(1997) and Raballo et al. (2000), who suggest that
neurogenesis from neuroepithelial progenitor cells requires
low concentrations of FGF2; as a result, those cells influenced
only by the low levels of FGF2 from inside the neuroepithe-
lium, namely, those situated at its basal portion, would be
subject to neural differentiation, while the cells capable of
proliferation are situated near to the apical side, that is, next
to the cerebral cavity, where they can receive the influence of
the FGF2 from the E-CSF.
Finally, the presence of FGF2 in the cerebrospinal fluid is
constant both during brain development and in the postnatal
period, in which it plays an important physiological role and is
involved in the physiopathology of certain neurodegenerative
disorders. In this paper, we show that the FGF2 of embryonal
cerebrospinal fluid also play a key role in the development of
the CNS.
The extraneural origin of E-CSF in the embryonal
cerebrospinal fluid
Taking into consideration both the fact that our results reveal
low levels of fgf2 expression in the neuroepithelium of the brain
primordium of chick embryos, when compared with other
extraneural structures, and, as we established previously, that
the neuroepithelium seems insufficient to maintain normal
levels of proliferation and neurogenesis, we suggest that the
FGF2 from E-CSF might have an extraneural origin.
In order to test this hypothesis, we have attempted to check
whether extraneural primordia (notochord) are capable of
liberating diffusible and active forms of FGF2, if this factor is
present in the serum of embryos during the stages we studied
and if it is able to pass from the serum to E-CSF.
In this paper, we demonstrate that during the initial
phases of chick embryo development, there are different
structures, such as the hepatic primordium, the mesonephros
and, above all, the notochord, which present much higher
levels of FGF2 expression than the neuroepithelium itself.
Moreover, we have seen that the notochord liberates different
soluble isoforms of FGF2, which are capable of activating
the replication and neurogenesis in vitro of neuroepithelial
cells. Such findings are consistent with previous studies
demonstrating the capacity of chick embryo notochord to
produce FGF2 (Hebrok et al., 1998); what is more,
ectopically implanted notochord induces in vivo an increasein the mitotic activity of the neuroblasts in chick spinal cord
(van Straaten et al., 1989).
Secondly, we have observed that HMW and LMW isoforms
of FGF2 are present in the serum of chick embryos at very early
stages of development (E 25 H.H.), which demonstrates the
existence of diffusible forms of FGF2 circulating, the origin of
which could be in the structures with high levels of mRNA
expression of fgf2, permitting it to act remotely on target cells.
Finally, we demonstrate that the FGF2 stained with
exogenous FITC injected into the embryonic vascular system
passes to the E-CSF in a short space of time, while other
proteins of the same or greater molecular weight are incapable
of this process. Considering that at these stages of development
the cavity of the embryonic brain is a physiologically sealed
system, surrounded exclusively by neuroepithelial cells in
which the choroid plexuses are yet to develop, we may affirm
that the FGF2-FITC has selectively traversed the neuroepithe-
lium in a basal–apical direction. These data suggest that there
might exist within the neuroepithelium some type of specific
transportation mechanism for this molecule, a matter which
requires further investigation. In adults, it has been proven that
the choroid plexuses are responsible for regulating the
concentration of FGF2 levels in cerebrospinal fluid (Stopa et
al., 2001). However, in early phases of embryonic development,
when the choroid plexus are undeveloped or not yet functional,
the neuroepithelium itself might assume this function. In this
regard, the existence has been shown of a mechanism that
selectively internalizes specific proteins in the E-CSF of chick
embryos (Moro and Uriel, 1981), which testifies to the
transportation capacity of this epithelium.
This paper contributes new ideas regarding the regulation
and differentiation of neuroepithelial cells in early stages of
chick embryo development, confirming the important trophic
role, previously described by us, of E-CSF in this species,
and providing evidence that FGF2 plays a key role in this
action.
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